Fulvestrant
It is an anti-estrogen medication. Fulvestrant is used to treat some hormone-related breast cancer.Treatment of postmenopausal women with estrogen receptor-positive, locally advanced or metastatic breast cancer for disease relapse on or after adjuvant antiestrogen therapy or disease progression on therapy with an antiestrogen.
Adult Females (including Elderly): Recommended dose : 500mg at intervals of 1 month, with an additional 500mg dose given 2 weeks after initial dose. Adolescents and children : Fulvestrant is not recommended for use in children or adolescents, as safety an efficacy have not been established in this age group.
Pregnancy, Lactation, Patients with known hypersensitivity to fulvestrant. Severe hepatic impairment.
Patients with Renal Impairment, hepatic impairement. Asthenia has been reported very commonly with fulvestrant, caution must be observed by those patients who experience this adverse reaction when driving or operating machinery.
Asthenia, injection site reactions Increased hepatic enzymes (ALT, AST, ALP) Urinary tract infections, Anorexia, Venous thromboembolism, hot flushes Hypersensitivity reactions.
Fulvestrant does not inhibit CYP3A4. No significant drug interaction have been found however precaution need to be taken with warfarin.
